Your browser doesn't support javascript.
loading
A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics.
Zhu, Sihao; Li, Ziyuan; Zheng, Dongye; Yu, Yue; Xiang, Jing; Ma, Xiao; Xu, Dongqing; Qiu, Jiajun; Yang, Ziyu; Wang, Zhiyi; Li, Jun; Sun, Hongfang; Chen, Weiqiang; Meng, Xiangxi; Lu, Yanye; Ren, Qiushi.
Afiliación
  • Zhu S; Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
  • Li Z; Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing 100191, China.
  • Zheng D; National Biomedical Imaging Center, Peking University, Beijing 100871, China.
  • Yu Y; Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 5181071, China.
  • Xiang J; Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
  • Ma X; Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
  • Xu D; Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing 100191, China.
  • Qiu J; National Biomedical Imaging Center, Peking University, Beijing 100871, China.
  • Yang Z; Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 5181071, China.
  • Wang Z; Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
  • Li J; Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
  • Sun H; Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing 100191, China.
  • Chen W; National Biomedical Imaging Center, Peking University, Beijing 100871, China.
  • Meng X; Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 5181071, China.
  • Lu Y; Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
  • Ren Q; Beijing National Laboratory for Molecular Sciences (BNLMS), Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Mol Ther Oncolytics ; 28: 182-196, 2023 Mar 16.
Article en En | MEDLINE | ID: mdl-36820302
Endogenous microRNAs (miRNA) in tumors are currently under exhaustive investigation as potential therapeutic agents for cancer treatment. Nevertheless, RNase degradation, inefficient and untargeted delivery, limited biological effect, and currently unclear side effects remain unsettled issues that frustrate clinical application. To address this, a versatile targeted delivery system for multiple therapeutic and diagnostic agents should be adapted for miRNA. In this study, we developed membrane-coated PLGA-b-PEG DC-chol nanoparticles (m-PPDCNPs) co-encapsulating doxorubicin (Dox) and miRNA-190-Cy7. Such a system showed low biotoxicity, high loading efficiency, and superior targeting ability. Systematic delivery of m-PPDCNPs in mouse models showed exceptionally specific tumor accumulation. Sustained release of miR-190 inhibited tumor angiogenesis, tumor growth, and migration by regulating a large group of angiogenic effectors. Moreover, m-PPDCNPs also enhanced the sensitivity of Dox by suppressing TGF-ß signal in colorectal cancer cell lines and mouse models. Together, our results demonstrate a stimulating and promising m-PPDCNPs nanoplatform for colorectal cancer theranostics.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Oncolytics Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Oncolytics Año: 2023 Tipo del documento: Article País de afiliación: China